Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 445

1.

Discussion of Schuemie et al: "A plea to stop using the case-control design in retrospective database studies".

Schneeweiss S, Suissa S.

Stat Med. 2019 Sep 30;38(22):4209-4212. doi: 10.1002/sim.8320. No abstract available.

PMID:
31489683
2.

Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men.

Dave CV, Schneeweiss S, Patorno E.

JAMA Intern Med. 2019 Sep 3. doi: 10.1001/jamainternmed.2019.2813. [Epub ahead of print] No abstract available.

PMID:
31479145
3.

When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and its Cardiovascular Safety.

Kim SC, Schneeweiss S.

Arthritis Rheumatol. 2019 Aug 30. doi: 10.1002/art.41092. [Epub ahead of print]

PMID:
31469243
4.

Continuing Professional Development Needs Amongst University of Toronto's Department of Radiation Oncology Faculty.

Zereshkian A, Wong R, Leifer R, Schneeweiss S, Tavares W, Paton M, Soliman H, Di Prospero L, Harnett N, Szumacher E.

J Cancer Educ. 2019 Aug 24. doi: 10.1007/s13187-019-01607-1. [Epub ahead of print]

PMID:
31446618
5.

Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution.

Glynn RJ, Lunt M, Rothman KJ, Poole C, Schneeweiss S, Stürmer T.

Pharmacoepidemiol Drug Saf. 2019 Aug 5. doi: 10.1002/pds.4846. [Epub ahead of print]

PMID:
31385394
6.

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.

Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E.

Ann Intern Med. 2019 Jul 30. doi: 10.7326/M18-3136. [Epub ahead of print]

PMID:
31357213
7.

Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches.

Bohn J, Schneeweiss S, Glynn RJ, Toh S, Wyss R, Desai R, Gagne JJ.

EGEMS (Wash DC). 2019 Jul 15;7(1):27. doi: 10.5334/egems.254.

8.

Choosing Among Common Data Models for Real-World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products.

Schneeweiss S, Brown JS, Bate A, Trifirò G, Bartels DB.

Clin Pharmacol Ther. 2019 Jul 22. doi: 10.1002/cpt.1577. [Epub ahead of print] Review.

PMID:
31330042
9.

Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study.

Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ.

Drug Saf. 2019 Jul 18. doi: 10.1007/s40264-019-00852-z. [Epub ahead of print]

PMID:
31321714
10.

Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem.

Kesselheim AS, Sinha MS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Avorn J, Dal Pan GJ.

Drug Saf. 2019 Jul 13. doi: 10.1007/s40264-019-00849-8. [Epub ahead of print]

PMID:
31302895
11.

Fracture Risk After Initiation of Use of Canagliflozin.

Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E.

Ann Intern Med. 2019 Jul 2;171(1):80. doi: 10.7326/L19-0320. No abstract available.

PMID:
31261403
12.

Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.

Patorno E, Schneeweiss S, Gopalakrishnan C, Martin D, Franklin JM.

Diabetes Care. 2019 Jun 25. pii: dc190069. doi: 10.2337/dc19-0069. [Epub ahead of print]

PMID:
31239281
13.

La déclaration RECORD-PE (Reporting of Studies Conducted Using Observational Routinely Collected Health Data Statement for Pharmacoepdemiology) : directives pour la communication des études realisées à partir de données de santé observationelles collectées en routine en pharmacoépidémiologie.

Langan SM, Schmidt SAJ, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sørensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI.

CMAJ. 2019 Jun 24;191(25):E689-E708. doi: 10.1503/cmaj.190347. French. No abstract available.

PMID:
31235490
14.

Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis.

Spoendlin J, Paik JM, Tsacogianis T, Kim SC, Schneeweiss S, Desai RJ.

JAMA Intern Med. 2019 Jun 1;179(6):741-749. doi: 10.1001/jamainternmed.2019.0045.

PMID:
31058913
15.

Evaluating utilization patterns of oral anticoagulants in routine care.

Gopalakrishnan C, Schneeweiss S, Bartels DB, Zint K, Santiago Ortiz A, Huybrechts KF.

J Thromb Haemost. 2019 Jul;17(7):1033-1043. doi: 10.1111/jth.14467. Epub 2019 May 29.

PMID:
31038824
16.

Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.

Kim SC, Pawar A, Desai RJ, Solomon DH, Gale S, Bao M, Sarsour K, Schneeweiss S.

Semin Arthritis Rheum. 2019 Oct;49(2):222-228. doi: 10.1016/j.semarthrit.2019.03.002. Epub 2019 Mar 9.

PMID:
30967248
17.

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.

Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S.

Circulation. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8.

PMID:
30955357
18.

Real-World Evidence of Treatment Effects: The Useful and the Misleading.

Schneeweiss S.

Clin Pharmacol Ther. 2019 Jul;106(1):43-44. doi: 10.1002/cpt.1405. Epub 2019 Apr 3. No abstract available.

PMID:
30942896
19.

Cardiovascular safety of linagliptin compared with other oral glucose-lowering agents in patients with type 2 diabetes: A sequential monitoring programme in routine care.

Patorno E, Gopalakrishnan C, Brodovicz KG, Meyers A, Bartels DB, Liu J, Kulldorff M, Schneeweiss S.

Diabetes Obes Metab. 2019 Aug;21(8):1824-1836. doi: 10.1111/dom.13735. Epub 2019 May 1.

PMID:
30941884
20.

Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.

Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S.

N Engl J Med. 2019 Mar 21;380(12):1128-1138. doi: 10.1056/NEJMoa1813751.

PMID:
30893533
21.

Graphical Depiction of Longitudinal Study Designs in Health Care Databases.

Schneeweiss S, Rassen JA, Brown JS, Rothman KJ, Happe L, Arlett P, Dal Pan G, Goettsch W, Murk W, Wang SV.

Ann Intern Med. 2019 Mar 19;170(6):398-406. doi: 10.7326/M18-3079. Epub 2019 Mar 12.

PMID:
30856654
22.

Theory meets practice: a commentary on VanderWeele's 'principles of confounder selection'.

Schneeweiss S.

Eur J Epidemiol. 2019 Mar;34(3):221-222. doi: 10.1007/s10654-019-00495-5. Epub 2019 Mar 6. No abstract available.

PMID:
30840182
23.

Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods.

Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ.

Pharmacoepidemiol Drug Saf. 2019 May;28(5):665-670. doi: 10.1002/pds.4729. Epub 2019 Feb 20.

PMID:
30786103
24.

Sequential Monitoring of the Comparative Effectiveness and Safety of Dabigatran in Routine Care.

Schneeweiss S, Gopalakrishnan C, Bartels DB, Franklin JM, Zint K, Kulldorff M, Huybrechts KF.

Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e005173. doi: 10.1161/CIRCOUTCOMES.118.005173.

PMID:
30764655
25.

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.

Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, Sarsour K, Schneeweiss S, Kim SC.

Ann Rheum Dis. 2019 Apr;78(4):456-464. doi: 10.1136/annrheumdis-2018-214367. Epub 2019 Jan 24.

PMID:
30679153
26.

A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data.

Bykov K, Schneeweiss S, Glynn RJ, Mittleman MA, Gagne JJ.

Clin Pharmacol Ther. 2019 Jul;106(1):238-244. doi: 10.1002/cpt.1376. Epub 2019 Mar 18.

PMID:
30663781
27.

Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use.

Gopalakrishnan C, Gagne JJ, Sarpatwari A, Dejene SZ, Dutcher SK, Levin R, Franklin JM, Schneeweiss S, Desai RJ.

Clin Pharmacol Ther. 2019 Jun;105(6):1513-1521. doi: 10.1002/cpt.1348. Epub 2019 Feb 25.

PMID:
30659590
28.

Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making.

Franklin JM, Glynn RJ, Martin D, Schneeweiss S.

Clin Pharmacol Ther. 2019 Apr;105(4):867-877. doi: 10.1002/cpt.1351. Epub 2019 Feb 25.

PMID:
30636285
29.

Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.

Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E.

Ann Intern Med. 2019 Feb 5;170(3):155-163. doi: 10.7326/M18-0567. Epub 2019 Jan 1.

30.

Measuring prevalence and incidence of chronic conditions in claims and electronic health record databases.

Rassen JA, Bartels DB, Schneeweiss S, Patrick AR, Murk W.

Clin Epidemiol. 2018 Dec 17;11:1-15. doi: 10.2147/CLEP.S181242. eCollection 2019.

31.

Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure.

Desai RJ, Lin KJ, Patorno E, Barberio J, Lee M, Levin R, Evers T, Wang SV, Schneeweiss S.

Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e004700. doi: 10.1161/CIRCOUTCOMES.118.004700.

PMID:
30562067
32.

The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation.

Bykov K, Mittleman MA, Glynn RJ, Schneeweiss S, Gagne JJ.

Epidemiology. 2019 Mar;30(2):204-211. doi: 10.1097/EDE.0000000000000944.

PMID:
30433922
33.

The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE).

Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB, Klungel O, Petersen I, Sorensen HT, Dixon WG, Guttmann A, Harron K, Hemkens LG, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang SV, Benchimol EI.

BMJ. 2018 Nov 14;363:k3532. doi: 10.1136/bmj.k3532. No abstract available.

34.

The Use of Statistical Process Control Charts to Evaluate Interprofessional Education Sessions Embedded Into a Pediatric Emergency In situ Resuscitation Program.

Pirie J, Cardenas S, Seleem W, Kljujic D, Schneeweiss S, Glanfield C, Principi T.

Simul Healthc. 2019 Apr;14(2):121-128. doi: 10.1097/SIH.0000000000000336. Review.

PMID:
30407960
35.

Virtual non-enhanced dual-energy CT reconstruction may replace true non-enhanced CT scans in the setting of suspected active hemorrhage.

Walter SS, Schneeweiß S, Maurer M, Kraus MS, Wichmann JL, Bongers MN, Lescan M, Bamberg F, Othman AE.

Eur J Radiol. 2018 Dec;109:218-222. doi: 10.1016/j.ejrad.2018.10.026. Epub 2018 Oct 28.

PMID:
30392950
36.

Comparative effectiveness and safety of antiplatelet drugs in patients with diabetes mellitus and acute coronary syndrome.

Spoendlin J, Gagne JJ, Lewey JJ, Patorno E, Schneeweiss S, Desai RJ.

Pharmacoepidemiol Drug Saf. 2018 Dec;27(12):1361-1370. doi: 10.1002/pds.4668. Epub 2018 Oct 31.

PMID:
30379372
37.

Using Previous Medication Adherence to Predict Future Adherence.

Kumamaru H, Lee MP, Choudhry NK, Dong YH, Krumme AA, Khan N, Brill G, Kohsaka S, Miyata H, Schneeweiss S, Gagne JJ.

J Manag Care Spec Pharm. 2018 Nov;24(11):1146-1155. doi: 10.18553/jmcp.2018.24.11.1146.

38.

Claims Data Studies of Direct Oral Anticoagulants Can Achieve Balance in Important Clinical Parameters Only Observable in Electronic Health Records.

Huybrechts KF, Gopalakrishnan C, Franklin JM, Zint K, Franca LR, Bartels DB, Landon J, Schneeweiss S.

Clin Pharmacol Ther. 2019 Apr;105(4):979-993. doi: 10.1002/cpt.1256. Epub 2018 Nov 11.

PMID:
30341980
39.

Radiation Dose Optimization in Pediatric Chest CT: Major Indicators of Dose Exposure in 1695 CT Scans over Seven Years.

Esser M, Hess S, Teufel M, Kraus MS, Schneeweiß S, Gatidis S, Schaefer JF, Tsiflikas I.

Rofo. 2018 Dec;190(12):1131-1140. doi: 10.1055/a-0628-7222. Epub 2018 Oct 11.

40.

General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment.

Najafzadeh M, Schneeweiss S, Choudhry NK, Avorn J, Gagne JJ.

Patient. 2019 Apr;12(2):235-246. doi: 10.1007/s40271-018-0329-1.

PMID:
30242575
41.

Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors.

Dave CV, Schneeweiss S, Patorno E.

Diabetes Obes Metab. 2019 Feb;21(2):434-438. doi: 10.1111/dom.13531. Epub 2018 Oct 11.

PMID:
30207042
42.

Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study.

Kim DH, Glynn RJ, Avorn J, Lipsitz LA, Rockwood K, Pawar A, Schneeweiss S.

J Gerontol A Biol Sci Med Sci. 2018 Aug 27. doi: 10.1093/gerona/gly197. [Epub ahead of print]

43.

Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials.

Wang SV, Schneeweiss S, Gagne JJ, Evers T, Gerlinger C, Desai R, Najafzadeh M.

Clin Pharmacol Ther. 2019 May;105(5):1156-1163. doi: 10.1002/cpt.1210. Epub 2018 Sep 24. Review.

PMID:
30107034
44.

Real-World Data Analytics Fit for Regulatory Decision-Making.

Schneeweiss S, Glynn RJ.

Am J Law Med. 2018 May;44(2-3):197-217. doi: 10.1177/0098858818789429.

PMID:
30106649
45.

Data Mining for Adverse Drug Events With a Propensity Score-matched Tree-based Scan Statistic.

Wang SV, Maro JC, Baro E, Izem R, Dashevsky I, Rogers JR, Nguyen M, Gagne JJ, Patorno E, Huybrechts KF, Major JM, Zhou E, Reidy M, Cosgrove A, Schneeweiss S, Kulldorff M.

Epidemiology. 2018 Nov;29(6):895-903. doi: 10.1097/EDE.0000000000000907.

PMID:
30074538
46.

Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects.

Schneeweiss S.

Clin Epidemiol. 2018 Jul 6;10:771-788. doi: 10.2147/CLEP.S166545. eCollection 2018. Review.

47.

Network-based approach to prediction and population-based validation of in silico drug repurposing.

Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabási AL, Loscalzo J.

Nat Commun. 2018 Jul 12;9(1):2691. doi: 10.1038/s41467-018-05116-5.

48.

Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation.

Krumme AA, Glynn RJ, Schneeweiss S, Choudhry NK, Tong AY, Gagne JJ.

Circ Cardiovasc Qual Outcomes. 2018 Jul;11(7):e004684. doi: 10.1161/CIRCOUTCOMES.118.004684.

PMID:
29991646
49.

Erratum: High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data.

Wyss R, Fireman B, Rassen JA, Schneeweiss S.

Epidemiology. 2018 Nov;29(6):e63-e64. doi: 10.1097/EDE.0000000000000886. No abstract available.

PMID:
29958191
50.

Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis.

Spoendlin J, Schneeweiss S, Tsacogianis T, Paik JM, Fischer MA, Kim SC, Desai RJ.

Am J Kidney Dis. 2018 Aug;72(2):178-187. doi: 10.1053/j.ajkd.2018.03.027. Epub 2018 Jun 8.

PMID:
29891194

Supplemental Content

Loading ...
Support Center